Olanzapine concentrations collected postmortem in patients treated with olanzapine long-acting injection

被引：1
|
作者：
McDonnell, D. P. [1 ]
Detke, H. C. [1 ]
Falk, M. [1 ]
Shatapathy, C. C. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2013年 / 23卷
关键词：
D O I：
10.1016/S0924-977X(13)70776-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.053
引用
收藏
页码：S489 / S490
页数：2
相关论文
共 50 条
  • [41] Cost effectiveness analysis of long-acting risperidone injection compared with olanzapine and fluphenazine decanoate in patients with schizophrenia
    Baca, E
    Bobes, J
    Cañas, F
    Leal, C
    Salvador, L
    Rubio, M
    Magaz, S
    Badía, X
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S238 - S238
  • [42] Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
    Ciudad, Antonio
    Anand, Ernie
    Berggren, Lovisa
    Casillas, Marta
    Schacht, Alexander
    Perrin, Elena
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 1737 - 1750
  • [43] Olanzapine long-acting post-injection syndrome: a case report and brief review
    Duran-Sindreu, Santiago F.
    Grasa-Bello, Eva
    Corripio-Collado, Illuminada
    Sauras-Quetcuti, Rosa B.
    Keymer-Gausset, Alejandro
    Roldan-Bejarano, Alexandra
    Alonso-Solis, Anna
    Figueras-Vilalta, Maria
    Alvarez-Martinez, Enric
    ACTAS ESPANOLAS DE PSIQUIATRIA, 2013, 41 (01): : 60 - 62
  • [44] Olanzapine-treated patients with psychotic disorders improved after changing to risperidone long-acting injectable
    Chrzanowski, W
    Latif, M
    Masiak, M
    Medori, R
    Gastpar, M
    EUROPEAN PSYCHIATRY, 2005, 20 : S66 - S66
  • [45] Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine
    Gastpar, M
    Masiak, M
    Latif, MA
    Frazzingaro, S
    Medori, R
    Lombertie, ER
    JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (05) : 32 - 38
  • [46] Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
    Wehring, Heidi J.
    Thedford, Sheryl
    Koola, Maju
    Kelly, Deanna L.
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2011, 3 : 107 - 123
  • [47] Olanzapine "long-acting" therapy in schizophrenic patients: clinical dimensions and plasma levels
    Paletta, S.
    Di Pace, C.
    Maffini, M.
    Reggiori, A.
    Mauri, M. C.
    Altamura, A. C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S552 - S553
  • [48] SWITCHING TO OLANZAPINE LONG-ACTING INJECTION FROM EITHER ORAL OLANZAPINE OR ANY OTHER ANTIPSYCHOTIC: COMPARATIVE POST-HOC ANALYSES
    Ciudad, Antonio
    Casillas, Marta
    Schacht, Alexander
    Anand, Ernie
    Perrin, Elena
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S260 - S260
  • [49] Clinical improvement with long-acting risperidone in patients previously receiving oral olanzapine
    Jones, R
    Lasser, R
    Bossie, C
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S303 - S304
  • [50] Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, Pierre-Michel
    Choukour, Moutaz
    Watson, Susan B.
    Brunner, Elizabeth
    Ascher-Svanum, Haya
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (04) : 426 - 434
12345